Showing posts with label cancer:. Show all posts
Showing posts with label cancer:. Show all posts

ovarian cancer:survical rates

What is the survival rate for ovarian cancer?
Every woman with ovarian cancer is treated as an individual case, depending on the stage of the disease and other personal factors, and so it is difficult to give a general prognosis.
If the cancer is diagnosed and treated early, between 80-100% of patients will survive for more than five years. Approximately 20% of women diagnosed at later stages will survive for more than five years. This figure, however, is improving all the time with better treatment. See 'How is Ovarian Cancer Treated?' for further discussion about survival rates.

ovarian cancer:how is oc staged


How Is Ovarian Cancer Staged?
Staging is the process of finding out how widespread a cancer is. Most ovarian cancers that are not obviously widespread are staged at the time of surgery. One of the goals of surgery for ovarian cancer is to obtain tissue samples for diagnosis and staging. In order to stage the cancer, samples of tissues are taken from different parts of the pelvis and abdomen and examined under the microscope.
Staging is very important because ovarian cancers have a different prognosis at different stages and are treated differently. The accuracy of the staging may determine whether or not a patient will be cured. If the cancer is not properly staged, then cancer that has spread outside the ovary may be missed and not treated. Once a stage has been given it does not change, even when the cancer comes back or spreads to new locations in the body.
Ask your cancer care team to explain the staging procedure. Also ask them if they will perform a thorough staging procedure. After surgery, ask what your cancer's stage is. In this way, you will be able to take part in making informed decisions about your treatment.
Ovarian cancer is staged according to the AJCC/TNM System. This describes the extent of the primary Tumor (T), the absence or presence of metastasis to nearby lymph Nodes (N), and the absence or presence of distant Metastasis (M). This closely resembles the system that is actually used by most gynecologic oncologists, called the FIGO system. Both rely on the results of surgery for the actual stages. Fallopian tube cancer is staged like ovarian cancer, but with different "T" categories. Primary peritoneal cancer (PPC) is staged like ovarian cancer, with all cases being either stage III or IV depending on whether the cancer has spread to distant sites.
T categories for ovarian cancer
Tx: No description of the tumor's extent is possible because of incomplete information.
T1: The cancer is confined to the ovaries -- one or both.
T1a: The cancer is only inside one ovary - it is not on the outside of the ovary, it doesn’t penetrate the tissue covering the ovary (called the capsule) and is not in fluid taken from the pelvis.
T1b: The cancer is inside both ovaries but doesn't penetrate to the outside and is not in fluid taken from the pelvis (like T1a except the cancer is in both ovaries).
T1c: The cancer is in one or both ovaries and is either on the outside of an ovary, grown through the capsule of an ovary, or is in fluid taken from the pelvis.
T2: The cancer is in one or both ovaries and is extending into pelvic tissues.
T2a: The cancer has spread (metastasized) to the uterus and/or the fallopian tubes but is not in fluid taken from the pelvis.
T2b: The cancer has spread to pelvic tissues besides the uterus and fallopian tubes but it is not in fluid taken from the pelvis.
T2c: The cancer has spread to the uterus and/or fallopian tubes and/or other pelvic tissues (like T2a or T2b) and is also in fluid taken from the pelvis.
T3: The cancer is in one or both ovaries and has spread to the abdominal lining outside the pelvis. This lining is called the peritoneum.
T3a: The cancer metastases are so small that they can not be seen except under a microscope.
T3b: The cancer metastases can be seen but no tumor is bigger than 2 centimeters (0.8 inches).
T3c: The cancer metastases are larger than 2 centimeters (0.8 inches).
T categories for fallopian tube cancer
Tx: No description of the tumor's extent is possible because of incomplete information.
Tis: Cancer cells are only in the inner lining of the fallopian tube. They have not grown into deeper layers. Also called carcinoma in situ.
T1: The cancer is in the fallopian tube(s), but has not grown outside of them.
T1a: The cancer is only inside one fallopian tube -- it has not grown through to the outside of the tube. It hasn't grown through the tissue covering the tumor (called the capsule) and is not in fluid taken from the pelvis.
T1b: The cancer is growing in both fallopian tubes -- it has not grown through to the outside of the tube. It hasn't grown through the tissue covering the tumor (called the capsule) and is not in fluid taken from the pelvis (like T1a but with tumor in both tubes).
T1c: The tumor is in one or both fallopian tubes and has either grown through the outer wall of the tube or cancer cells are found in fluid taken from the pelvis.
T2: The tumor has grown from one or both fallopian tubes into the pelvis.
T2a: The cancer is growing into the uterus and/or the ovaries.
T2b: The cancer is growing into other parts of the pelvis.
T2c: The cancer has spread from the fallopian tubes into other parts of the pelvis and cancer cells are found in fluid taken from the pelvis (either from ascites or from washings obtained at surgery.
T3: The tumor has spread outside the pelvis to the lining of the abdomen.
T3a: The areas of cancer spread outside the pelvis can only be found when the area is biopsied and looked at under the microscope.
T3b: The areas of spread can be seen with the naked eye, but are 2 cm or less in size (less than an inch).
T3c: The areas of spread are greater than 2 cm in size.
N categories
N categories indicate whether or not the cancer has spread to regional (nearby) lymph nodes.
Nx: No description of lymph node involvement is possible because of incomplete information.
N0: No lymph node involvement.
N1: Cancer cells are found in the lymph nodes close to tumor.
M categories
M categories indicate whether or not the cancer has spread to distant organs, such as the liver, lungs, or non-regional lymph nodes.
Mx: No description of distant spread is possible because of incomplete information.
M0: No distant spread.
M1: Cancer has spread to the inside of the liver, to the lungs, or other organs.
Grade categories
(The higher the grade, the more likely it is that the cancer will spread.)
Grade 1: Well differentiated -- looks similar to normal ovarian tissue.
Grade 2: Not as well differentiated -- looks less like ovarian tissue.
Grade 3: Poorly differentiated – does not look like ovarian tissue.
Stage grouping
Once a patient's T, N, and M categories have been determined, this information is combined in a process called stage grouping to determine the stage, expressed in Roman numerals from stage I (the least advanced stage) to stage IV (the most advanced stage). The following table illustrates how TNM categories are grouped together into stages. This stage grouping also applies to fallopian tube carcinoma.
What the stages of ovarian cancer mean
Stage I
The cancer is still contained within the ovary (or ovaries).
Stage IA (T1a, N0, M0): Cancer has developed in one ovary, and the tumor is confined to the inside of the ovary. There is no cancer on the outer surface of the ovary. Laboratory examination of washings from the abdomen and pelvis did not find any cancer cells.
Stage IB (T1b, N0, M0): Cancer has developed within both ovaries without any tumor on their outer surfaces. Laboratory examination of washings from the abdomen and pelvis did not find any cancer cells.
Stage IC (T1c, N0, M0): The cancer is present in one or both ovaries and one or more of the following are present:
Cancer is on the outer surface of at least one of the ovaries.
In the case of cystic tumors (fluid-filled tumors), the capsule (outer wall of the tumor) has ruptured (burst)
Laboratory examination found cancer cells in fluid or washings from the abdomen.
Stage II
The cancer is in one or both ovaries and has involved other organs (such as the uterus, fallopian tubes, bladder, the sigmoid colon, or the rectum) within the pelvis.
Stage IIA (T2a, N0, M0): The cancer has spread to or has actually invaded (grown into) the uterus or the fallopian tubes, or both. Laboratory examination of washings from the abdomen did not find any cancer cells.
Stage IIB (T2b, N0, M0): The cancer has spread to other nearby pelvic organs such as the bladder, the sigmoid colon, or the rectum. Laboratory examination of fluid from the abdomen did not find any cancer cells.
Stage IIC (T2c, N0, M0): The cancer has spread to pelvic organs as in stages IIA or IIB and laboratory examination of the washings from the abdomen found evidence of cancer cells.
Stage III
The cancer involves one or both ovaries, and one or both of the following are present: (1) cancer has spread beyond the pelvis to the lining of the abdomen; (2) cancer has spread to lymph nodes.
Stage IIIA (T3a, N0, M0): During the staging operation, the surgeon can see cancer involving the ovary or ovaries, but no cancer is grossly visible (can be seen without using a microscope) in the abdomen and the cancer has not spread to lymph nodes. However, when biopsies are checked under a microscope, tiny deposits of cancer are found in the lining of the upper abdomen.
Stage IIIB (T3b, N0, M0): There is cancer in one or both ovaries, and deposits of cancer large enough for the surgeon to see, but smaller than 2 cm (about 3/4 inch) across, are present in the abdomen. Cancer has not spread to the lymph nodes.
Stage IIIC: The cancer is in one or both ovaries, and one or both of the following are present:
Cancer has spread to lymph nodes (any T, N1, M0)
Deposits of cancer larger than 2 cm (about 3/4 inch) across are seen in the abdomen (T3c, N0, M0).
Stage IV (any T, any N, M1):
This is the most advanced stage of ovarian cancer. In this stage the cancer has spread to the inside of the liver, the lungs, or other organs located outside of the peritoneal cavity. (The peritoneal cavity, or abdominal cavity is the area enclosed by the peritoneum, a. membrane that lines the inner abdomen and covers most of its organs.). Finding ovarian cancer cells in the fluid around the lungs (called pleural fluid) is also evidence of stage IV disease.
Recurrent ovarian cancer: This means that the disease went away with treatment but then came back (recurred).
Survival by stage
The numbers below are based on patients diagnosed from 1988 to 2001. These numbers come from the National Cancer Institute, SEER Data Base.
Invasive epithelial ovarian cancer
Stage
Relative 5-Year Survival Rate
I
89%
IA
94%
IB
91%
IC
80%
II
66%
IIA
76%
IIB
67%
IIC
57%
III
34%
IIIA
45%
IIIB
39%
IIIC
35%
IV
18%
Ovarian tumors of low malignant potential
Stage
Relative 5-yr Survival Rate
I
99%
II
98%
III
96%
IV
77%
Germ cell tumors of the ovary
Stage
Relative 5-yr Survival Rate
I
98%
II*
80%
III
84%
IV
55%
*stage II cancer survival not based on many cases - may not be reliable
Fallopian tube carcinoma
Stage
Relative 5-yr Survival Rate
I
93%
II*
74%
III
66%
IV
40%
The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. Five-year rates are used to produce a standard way of discussing prognosis. Of course, many people live much longer than 5 years. Five-year relative survival rates take into account that people will die of other causes and compare the observed survival with that expected for people without ovarian cancer. This is a better way to describe the deaths from ovarian cancer.

ovarian cancer:chemotherapy

Chemotherapy
Chemotherapy uses anticancer drugs to kill cancer cells. Most women have chemotherapy for ovarian cancer after surgery. Some women have chemotherapy before surgery.
Usually, more than one drug is given. Drugs for ovarian cancer can be given in different ways:
By vein (IV): The drugs can be given through a thin tube inserted into a vein.
By vein and directly into the abdomen: Some women get IV chemotherapy along with intraperitoneal (IP) chemotherapy. For IP chemotherapy, the drugs are given through a thin tube inserted into the abdomen.
By mouth: Some drugs for ovarian cancer can be given by mouth.
Chemotherapy is given in cycles. Each treatment period is followed by a rest period. The length of the rest period and the number of cycles depend on the anticancer drugs used.
You may have your treatment in a clinic, at the doctor's office, or at home. Some women may need to stay in the hospital during treatment.
The side effects of chemotherapy depend mainly on which drugs are given and how much. The drugs can harm normal cells that divide rapidly:
Blood cells: These cells fight infection, help blood to clot, and carry oxygen to all parts of your body. When drugs affect your blood cells, you are more likely to get infections, bruise or bleed easily, and feel very weak and tired. Your health care team checks you for low levels of blood cells. If blood tests show low levels, your health care team can suggest medicines that can help your body make new blood cells.
Cells in hair roots: Some drugs can cause hair loss. Your hair will grow back, but it may be somewhat different in color and texture.
Cells that line the digestive tract: Some drugs can cause poor appetite, nausea and vomiting, diarrhea, or mouth and lip sores. Ask your health care team about medicines that help with these problems.
Some drugs used to treat ovarian cancer can cause hearing loss, kidney damage, joint pain, and tingling or numbness in the hands or feet. Most of these side effects usually go away after treatment ends.
You may find it helpful to read NCI's booklet Chemotherapy and You: A Guide to Self-Help During Cancer Treatment.

pancreatic cancer:

Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease. The prognosis is generally poor; less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still extremely rare. About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells. Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.

Contents:
1 Signs and symptoms
1.1 Presentation
1.2 Predisposing factors
1.2.1 Alcohol
2 Diagnosis
3 Treatment
3.1 Surgery
3.2 Chemotherapy
4 Prognosis
5 Prevention
6 See also
7 References
8 External links



Signs and symptoms;

Presentation:
Pancreatic cancer is sometimes called a "silent killer" because early pancreatic cancer often does not cause symptoms and the later symptoms are usually non-specific and varied.Therefore, pancreatic cancer is often not diagnosed until it is advanced.

Common symptoms include:

Pain in the upper abdomen that typically radiates to the back (seen in carcinoma of the body or tail of the pancreas)
Loss of appetite (anorexia), and/or nausea and vomiting
Significant weight loss
Painless jaundice (yellow skin/eyes, dark urine) when a cancer of the head of the pancreas (about 60% of cases) obstructs the common bile duct as it runs through the pancreas. This may also cause pale-colored stool and steatorrhea.
Trousseau sign, in which blood clots form spontaneously in the portal blood vessels, the deep veins of the extremities, or the superficial veins anywhere on the body, is sometimes associated with pancreatic cancer.

Diabetes mellitus, or elevated blood sugar levels. Many patients with pancreatic cancer develop diabetes months to even years before they are diagnosed with pancreatic cancer, suggestion that new onset diabetes in an elderly individual may be an early warning sign of pancreatic cancer.

Clinical depression has been reported in association with pancreatic cancer, sometimes presenting before the cancer is diagnosed. However, the mechanism for this association is not known.

Predisposing factors:
Risk factors for pancreatic cancer include:
Age (particularly over 60)
Male gender
African-American ethnicity
Smoking. Cigarette smoking has a risk ratio of 1.74 with regard to pancreatic cancer; a decade of non-smoking after heavy smoking is associated with a risk ratio of 1.2.
Diets low in vegetables and fruitsDiets high in red meat
Obesity
Diabetes mellitus is both risk factor for pancreatic cancer, and, as noted earlier, new onset diabetes can be an early sign of the disease.
Chronic pancreatitis has been linked, but is not known to be causal. The risk of pancreatic cancer in individuals with familial pancreatitis is particularly high.
Helicobacter pylori infection
Family history, 5–10% of pancreatic cancer patients have a family history of pancreatic cancer. The genes responsible for most of this clustering in families have yet to be identified. Pancreatic cancer has been associated with the following syndromes; autosomal recessive ataxia-telangiectasia and autosomal dominantly inherited mutations in the BRCA2 gene and PALB2 gene, Peutz-Jeghers syndrome due to mutations in the STK11 tumor suppressor gene, hereditary non-polyposis colon cancer (Lynch syndrome), familial adenomatous polyposis, and the familial atypical multiple mole melanoma-pancreatic cancer syndrome (FAMMM-PC) due to mutations in the CDKN2A tumor suppressor gene.Gingivitis or periodontal disease

Alcohol:
It is controversial whether alcohol consumption is a risk factor for pancreatic cancer. Drinking alcohol excessively is a major cause of chronic pancreatitis, which in turn predisposes to pancreatic cancer, but "chronic pancreatitis that is due to alcohol doesn't increase risk as much as other types of chronic pancreatitis."[clarification needed)Overall, the association is consistently weak and the majority of studies have found no association.
Some studies suggest a relationship, with risk increasing with increasing amount of alcohol intake.Risk is greatest in heavy drinkers mostly on the order of four or more drinks per day. But there appears to be no increased risk for people consuming up to 30g of alcohol a day so most of the U.S. consumes alcohol at a level that "is probably not a risk factor for pancreatic cancer.
Several studies caution that their findings could be due to confounding factors.Even if a link exists, it "could be due to the contents of some alcoholic beverages' other than the alcohol itself. One Dutch study even found that drinkers of white wine had lower risk.A pooled analysis concluded, "Our findings are consistent with a modest increase in risk of pancreatic cancer with consumption of 30 or more grams of alcohol per day.

Diagnosis:
Most patients with pancreatic cancer experience pain, weight loss, or jaundice.
Pain is present in 80 to 85 percent of patients with locally advanced or advanced metastic disease. The pain is usually felt in the upper abdomen as a dull ache that radiates straight through to the back. It may be intermittent and made worse by eating. Weight loss can be profound; it can be associated with anorexia, early satiety, diarrhea, or steatorrhea. Jaundice is often accompanied by pruritus and dark urine. Painful jaundice is present in approximately one-half of patients with locally unresectable disease, while painless jaundice is present in approximately one-half of patients with a potentially resectable and curable lesion.

The initial presentation varies according to location of the cancer. Malignancies in the pancreatic body or tail usually present with pain and weight loss, while those in the head of the gland typically present with steatorrhea, weight loss, and jaundice. The recent onset of atypical diabetes mellitus, a history of recent but unexplained thrombophlebitis (Trousseau sign), or a previous attack of pancreatitis are sometimes noted.

Courvoisier sign defines the presence of jaundice and a painlessly distended gallbladder as strongly indicative of pancreatic cancer, and may be used to distinguish pancreatic cancer from gallstones.

Tiredness, irritability and difficulty eating due to pain also exist. Pancreatic cancer is usually discovered during the course of the evaluation of aforementioned symptoms.

Liver function tests can show a combination of results indicative of bile duct obstruction (raised conjugated bilirubin, γ-glutamyl transpeptidase and alkaline phosphatase levels). CA19-9 (carbohydrate antigen 19.9) is a tumor marker that is frequently elevated in pancreatic cancer. However, it lacks sensitivity and specificity. When a cutoff above 37 U/mL is used, this marker has a sensitivity of 77% and specificity of 87% in discerning benign from malignant disease. CA 19-9 might be normal early in the course, and could be elevated due to benign causes of biliary obstruction.Imaging studies, such as computed tomography (CT scan) can be used to identify the location of the cancer. Endoscopic ultrasound (EUS) is another procedure that can help visualize the location and can serve to guide a percutaneous needle biopsy, which is necessary to establish a definitive diagnosis.

Treatment:

surgery:Treatment of pancreatic cancer depends on the stage of the cancer.[35] The Whipple procedure is the most common surgical treatment for cancers involving the head of the pancreas. It can only be performed if the patient is likely to survive major surgery and if the cancer is localized without invading local structures or metastasizing. It can therefore only be performed in the minority of cases.

Spleen-preserving distal pancreatectomy can also be used as a method to remove a cancer running through centre of pancreas; this is invasive surgery, resulting in loss of body and tail. Cancers of the tail of the pancreas can be resected using a procedure known as a distal pancreatectomy.[35] Recently, localized cancers of the pancreas have been resected using minimally invasive (laparoscopic) approaches.
After surgery, adjuvant chemotherapy with gemcitabine has in several large randomized studies been shown to significantly increase the 5-year survival.
Surgery can be performed for palliation, if the malignancy is invading or compressing the duodenum or colon. In that case, bypass surgery might overcome the obstruction and improve quality of life, but it is not intended as a cure.

Chemotherapy:
In patients not suitable for resection with curative intent, palliative chemotherapy may be used to improve quality of life and gain a modest survival benefit. Gemcitabine was approved by the United States Food and Drug Administration in 1998 after a clinical trial reported improvements in quality of life in patients with advanced pancreatic cancer. This marked the first FDA approval of a chemotherapy drug for a non-survival clinical trial endpoint.

Prognosis:
Patients diagnosed with pancreatic cancer typically have a poor prognosis partly because the cancer usually causes no symptoms early on, leading to locally advanced or metastatic disease at time of diagnosis. Median survival from diagnosis is around 3 to 6 months; 5-year survival is less than 5%.With 37,170 cases diagnosed in the United States in 2007, and 33,700 deaths, pancreatic cancer has one of the highest fatality rates of all cancers and is the fourth highest cancer killer in the United States among both men and women. Although it accounts for only 2.5% of new cases, pancreatic cancer is responsible for 6% of cancer deaths each year.
Pancreatic cancer may occasionally result in diabetes. Insulin production is hampered and it has been suggested that the cancer can also prompt the onset of diabetes and vice versa. Thus diabetes is both a risk factor for the development of pancreatic cancer and diabetes can be an early sign of the disease in the elderly.


Prevention:
According to the American Cancer Society, there are no established guidelines for preventing pancreatic cancer, although cigarette smoking has been reported as responsible for 20–30% of pancreatic cancers.
The ACS recommends keeping a healthy weight, and increasing consumption of fruits, vegetables, and whole grains while decreasing red meat intake, although there is no consistent evidence that this will prevent or reduce pancreatic cancer specifically.